Recently, Sirio Pharma stated on the Shenzhen Stock Exchange interactive platform that exports from its China production facilities to the United States account for less than 15% of the company’s total revenue. The company is actively taking multiple measures to control the impact of reciprocal tariffs on its U.S. export business. Sirio has promptly initiated discussions with clients to share the rising tariff costs. In addition, the reciprocal tariff policy has created significant opportunities for the development of the company’s core BF business. Some clients have begun considering shifting part of their product manufacturing to Sirio’s local plant in the United States, and this is currently being actively pursued. (Source: National Business Daily)
Sign Up to Receive China Updates Weekly Newsletter for FREE, HERE
Visit HPA-China’s Information Hub, HERE